IGF2 regulates proliferation, differentiation, and mitochondrial bioenergetics in human satellite cells Authors: Ramouna Voshtani, Pengbo Hou, Zhanhong Liu, Lijuan Cao, Chao Feng, Changshun Shao, Yufang Shi, Jiankai Fang Published: 2025 ABSTRACT AbstractInsulin-like growth factors (IGFs) are key regulators of the stem cell niche, playing critical roles in the proliferation and differentiation of stem cells into various lineages, including skeletal muscle. While IGF2 is known to influence muscle development, its specific effects and mechanisms in human skeletal muscle remain incompletely understood. In this study, we demonstrate that IGF2 is a key regulator of human satellite cell (huSC) proliferation, differentiation, and mitochondrial bioenergetics. Using primary huSCs cultured under defined myogenic conditions, we show that IGF2 significantly enhances myoblast proliferation and promotes differentiation via upregulation of myogenic regulatory factors and activation of the IGF1 receptor (IGF1R) pathway. Knockdown of endogenous IGF2 impaired these processes, while exogenous supplementation restored myogenic potential. Notably, IGF2 also improved mitochondrial function, evidenced by increased oxygen consumption rate, mitochondrial mass, oxidative phosphorylation protein expression, and intracellular ATP production. These effects were primarily mediated through IGF1R signaling, with IGF2R playing a modulatory role in regulating IGF2 availability. Our findings reveal that IGF2 not only initiates structural differentiation but also drives metabolic reprogramming in huSCs, highlighting its dual role in supporting muscle regeneration and energy homeostasis. These insights highlight IGF2 as a promising therapeutic target for muscle-wasting conditions such as muscular dystrophy and age-related sarcopenia and suggest its broader potential in regenerative medicine strategies.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13062-025-00716-w.Keywords: Myogenesis, Satellite cells, Insulin-like growth factors, Metabolic reprogramming Introduction Skeletal muscle is a highly dynamic and metabolically active tissue, constituting nearly 50% of total body mass and accounting for approximately 50–75% of the body’s protein stores [1]. Its primary role in facilitating movement through voluntary contraction is well-established; however, skeletal muscle also plays critical roles in thermogenesis, systemic glucose and lipid metabolism, and endocrine regulation. Dysfunction or degeneration of skeletal muscle, as observed in conditions such as sarcopenia, muscular dystrophies, or cachexia, is associated with significant morbidity and a reduced quality of life. Therefore, understanding the cellular and molecular mechanisms that govern muscle development, regeneration, and metabolism is essential for developing effective therapeutic interventions. Skeletal muscle development and myogenesis initiate during embryonic life with the specification of mesodermal progenitor cells into the myogenic lineage. These cells, called myoblasts, undergo a proliferative phase before exiting the cell cycle, differentiating, and fusing to form multinucleated myotubes, which ultimately mature into functional myofibers [2]. This highly coordinated process is regulated by a family of transcription factors collectively termed the myogenic regulatory factors (MRFs), which include MYOD, MYF5, MYOG, and MRF4 [3, 4]. These factors coordinate lineage commitment, proliferation, and terminal differentiation. Most importantly, each of the four MRFs has been shown to induce myogenic differentiation when ectopically expressed in non-muscle cell types, underscoring their key regulatory functions [5–7]. In adult organisms, skeletal muscle regeneration is driven by a population of muscle-resident stem cells known as satellite cells [8]. These cells reside in a quiescent state beneath the basal lamina of muscle fibers and are activated in response to muscle damage, mechanical load, or systemic stimuli [9, 10]. Upon activation, satellite cells re-enter the cell cycle, proliferate, and either differentiate to contribute to new or repaired myofibers or undergo self-renewal to maintain the stem cell pool. The successful execution of these programs is dependent on the reactivation of myogenic programs, including MRF expression, and the integration of extracellular signals such as cytokines and growth factors. Despite decades of research into myogenic regulation, the interplay between growth factor signaling and cellular bioenergetics during human muscle regeneration remains poorly understood. Among the most prominent growth factors involved in muscle regeneration are insulin-like growth factors (IGFs), particularly IGF1 and IGF2. While IGF1 is well characterized for its roles in promoting myoblast proliferation, differentiation, and protein synthesis, the specific contributions of IGF2—particularly in adult human satellite cells (huSCs)—remain poorly defined [11–16]. IGF2, a peptide hormone structurally similar to IGF1, is predominantly expressed during fetal development but also plays functional roles in adult tissues, including skeletal muscle. Several in vitro studies have demonstrated that IGF2 supports myoblast differentiation and may act at later stages of myogenesis than IGF1 [17, 18]. Notably, a unique aspect of IGF2 biology is its interaction with the IGF2 receptor (IGF2R), which differs significantly from IGF1R in its function. In contrast to IGF1R, IGF2R lacks intrinsic kinase activity and does not initiate canonical signal transduction upon ligand binding. Instead, IGF2R acts as a clearance receptor that internalizes and targets IGF2 for lysosomal degradation, thereby modulating the availability of free IGF2 and limiting its signaling potential [19, 20]. This regulatory mechanism is crucial for maintaining tissue homeostasis and preventing aberrant activation of growth pathways, which may lead to tumorigenesis or abnormal tissue growth. Additionally, IGF2 has been shown to activate IGF1R, triggering intracellular signaling cascades similar to those induced by IGF1, including the MAPK/ERK1/2 and the PI3K/AKT/mTOR pathways [21, 22]. Evidence shows that IGF2 regulates the expression of myogenic genes such as MYOD and MYOG via AKT activation [23–25]. While IGF2 is thought to promote the later phases of differentiation [26], its precise molecular and metabolic effects in primary huSCs have not been comprehensively investigated. Notably, most prior research on IGF2 has been conducted using immortalized myoblast cell lines or non-human models, creating a critical gap in understanding how IGF2 regulates proliferation, differentiation, and energy metabolism in human primary satellite cells. Although most studies on IGFs have focused on their proliferative and differentiative functions, recent research underscores the critical role of IGF signaling in cellular energy metabolism. Satellite cell activation, proliferation, and differentiation are metabolically demanding processes that require precise coordination between signaling pathways and bioenergetic outputs. The transition from glycolysis to oxidative phosphorylation is essential as myoblasts differentiate into mature myotubes. While IGF1 has been shown to link growth signaling to mitochondrial biogenesis [27, 28], the role of IGF2 in metabolic remodeling and mitochondrial function in huSCs remains largely unexplored. This gap is especially significant because energy metabolism not only supports differentiation but also influences stem cell fate decisions and regenerative capacity. Therefore, this study offers the first comprehensive analysis of IGF2’s role in huSCs, demonstrating that IGF2 enhances cell proliferation and promotes myogenic differentiation via IGF1R-dependent mechanisms. These effects are accompanied by increased mitochondrial respiration and ATP production, highlighting IGF2’s essential role in meeting the bioenergetic demands of myogenic progression. Together, these findings provide a novel framework for understanding how IGF2 integrates signaling and metabolic pathways during human muscle regeneration. Methods Isolation of huSCs using FACS Human skeletal muscle tissue was obtained with informed consent in compliance with the Ethical Committee of the First Affiliated Hospital of Soochow University (Approval Number: ECSU-201900214). All tissue samples were collected from orthopedic trauma patients following informed consent. Gastrocnemius muscle specimens were used for all experiments. The muscle tissue was placed in sterile 50-ml centrifuge tubes containing low-glucose DMEM and processed within three hours of collection. Isolation and culture of huSCs were performed following established protocols [29, 30]. To isolate the huSCs, human skeletal muscle tissue was dissociated into single cells through enzymatic digestion with collagenase II (750 U/mL, Gibco, San Francisco, CA) for 1 h at 37 °C on a shaker. The digested tissues were washed once with cold Hanks’ Balanced Salt Solution (HBSS) and centrifuged at 500 g for 5 min. A second incubation was performed with collagenase II (100 U/mL) and dispase (11 U/mL, Gibco) for 30 min at 37 °C on a shaker. The digested tissue was filtered through a 40-µm cell strainer. Next, cells were incubated with fluorescently labeled antibodies against CD29, CD56, and EGFR for positive selection, and CD31, CD34, and CD45 for negative selection, to exclude non-huSCs. All antibodies were used at approximately 1 µg per 10⁷ cells. After staining, cells were sorted using a FACS machine, and live huSCs (CD29+/CD56+/EGFR+/CD31−/CD34−/CD45−) were collected. Details of huSC characterization are shown in Supplementary Figure S4. huSC expansion and differentiation Culture plates were coated with extracellular matrix protein (ECM, Sigma) at a 1:500 (v/v) dilution in low-glucose DMEM. Sorted huSCs were expanded every 2 days in myogenic proliferation medium, which consisted of a 1:1 mixture of DMEM and MCDB 131, supplemented with 20% FBS, 1% insulin-transferrin-selenium (ITS, Invitrogen), 1% penicillin-streptomycin, and 0.1% p38 inhibitor. The p38 inhibitor helps block the differentiation of huSCs, thus promoting their self-renewal properties [29, 30]. Cultured huSCs were differentiated in myogenic cell differentiation medium, which contained DMEM with 5% horse serum for over one week. Silencing of IGF2 expression by shRNA To achieve IGF2 knockdown, huSCs were transduced with IGF2-targeting short hairpin RNA (shRNA) carried by a lentivirus vector (PLV3/H1/GFP/Puro, GenePharma, Shanghai, China). The shRNA target sequence for IGF2 was 5′-GAAGTCGATGCTGGTGCTTCT-3′. The scrambled shRNA target sequence was 5′-TTCTCCGAACGTGTCACGT-3′. huSCs were incubated with lentivirus and polybrene (5 µg/mL, GenePharma) for 12 h. Puromycin (5 µg/mL, Gibco) was added to the culture medium to select successfully transduced cells. Western blot analysis Cells were lysed in RIPA buffer supplemented with PMSF, protease, and phosphatase inhibitors. Total protein concentration was quantified by the BCA Protein Assay Kit (Cat#23227; Thermo Fisher, Waltham, MA). Twenty µg of proteins were loaded and separated on SDS-PAGE gels. Proteins were transferred onto a PVDF membrane by wet transfer. The membrane was blocked in TBST with 5% BSA and probed with primary antibodies against IGF1R (Cat#9750, Cell Signaling Technology), p-IGF1R (Cat#3021, Cell Signaling Technology), IGF2R (Cat#14364, Cell Signaling Technology), p-IGF2R (Cat#PA5-64521, Invitrogen), IGF2 (Cat#ab9574, Abcam), MYOG (Cat#ab1835, Abcam), MyHC (Cat#MAB4470, R&D Systems), and Total oxidative phosphorylation (Cat#ab110413, Abcam). Images were acquired using HRP-conjugated secondary antibodies. RNA isolation and qRT-PCR Total RNA of each sample was extracted by Trizol (Thermo Fisher). According to the manufacturer’s protocol, cDNA was prepared using PrimeScriptRT Master Mix (Invitrogen) with 1 µg RNA template. mRNA levels were quantified by quantitative real-time PCR (qRT-PCR) using SYBR Green Master Mix (Thermo Fisher). Primer sequences were as follows: IGF2 (Forward: 5′-CTTGGACTTTGAGTCAAATTGG-3′, Reverse: 5′-GGTCGTGCCAATTACATTTCA-3′), PAX7 (Forward: 5′-ACCCCTGCCTAACCACATC-3′, Reverse: 5′-GCGGCAAAGAATCTTGGAGAC-3′), MYOD1 (Forward: 5′-CGCCATCCGCTATATCGAGG-3′, Reverse: 5′-CTGTAGTCCATCATGCCGTCG-3′), MYHC (Forward: 5′-CTGGAGGATGAATGCTCAGAGC-3′, Reverse: 5′-CCCAGAGAGTTCCTCAGTAAGG-3′), HK2 (Forward: 5′-GAGCCACCACTCACCCTACT-3′, Reverse: 5′-CCAGGCATTCGGCAATGTG-3′), PGAM1 (Forward: 5′-ACGTGTACTGATTGCAGCC-3′, Reverse: 5′-CGCCGGCCTTCACTTCT-3′), PFK1 (Forward: 5′-GGGGATGCTCAAGGTATGAAC-3′, Reverse: 5′-TCGGCCTCTGCGATGTTTG-3′), ENO1 (Forward: 5′-AAAGCTGGTGCCGTTGAGAA-3′, Reverse: 5′-GGTTGTGGTAAACCTCTGCTC-3′), PKM2 (Forward: 5′-ATGTCGAAGCCCCATAGTGAA-3′, Reverse: 5′-TGGGTGGTGAATCAATGTCCA-3′). 2-NBDG uptake assay 2 × 105 cells were seeded in a 12-well plate and cultured in growth medium for one day. When they reached 90% confluence, the medium was switched to differentiation medium consisting of DMEM supplemented with 5% horse serum. After 3 days, cells were rinsed twice with PBS and incubated with 2-NBDG (1000x dilution in DMEM) for 1 h. Trypsinized cells were then analyzed by flow cytometer using the BD FACSAria Fusion (BD Biosciences). Raw data were analyzed using FlowJo software. Lactate assay The lactate level in the cell supernatant was measured using the Lactate Assay Kit (Cat#MAK064-1KT, Sigma-Aldrich) according to the manufacturer’s instructions. Cells were seeded at a density of 2 × 104 cells/well in a 96-well plate and cultured for 3 days in differentiation medium with low and high doses of IGF2. The cell culture supernatant was then collected and mixed with L-Lactate assay solution for 30 min at 37 °C in an incubator. The concentration of L-Lactate was measured by absorbance at 570 nm. Cellular bioenergetics Cellular bioenergetics were analyzed on a Seahorse extracellular flux bioanalyzer (XF24). Briefly, cells were seeded at a density of 5 × 104 cells/well in a Seahorse XF24 plate. Cells were cultured for 3 days in differentiation medium with low and high doses of IGF2. Immediately prior to the assay, cultured cells were washed twice in minimal assay media (Seahorse Biosciences, 37 °C, pH 7.40), supplemented with 2.5 mM glucose and 1 mM sodium pyruvate. All cells were equilibrated in minimal assay media for 1 h in a non-CO2 incubator immediately prior to the assay. Basal respiration was recorded and then the injections via a pre-hydrated XF24 sensor cartridge were carried out consecutively as follows: only media DMEM (2.5 mM D-glucose), oligomycin (2 mM, an inhibitor of ATP synthesis used to determine respiration linked to ATP synthesis), carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP, 1 mM, the mitochondrial uncoupler used to measure maximal respiration capacity), and a combined solution of rotenone and antimycin A (1 mM, inhibitors of mitochondrial complexes III and I, respectively). The oxygen consumption rate, which indicates the rate of mitochondrial respiration, was measured at the baseline levels and after every injection. Intracellular ATP content was determined luminometrically using an enhanced ATP assay kit (Cat#S0027, Beyotime), according to the manufacturer’s instructions. Briefly, the ATP working solution was added to the assay wells at room temperature, followed by the tissue lysis supernatant. The Relative Light Unit (RLU) was measured with a luminometer after mixing for at least 2 s at room temperature. For MitoTracker fluorescence staining, 2 × 10⁵ cells were seeded in a 12-well plate and cultured in differentiation medium containing IGF2 for three days. MitoTracker Green FM (Cat#M7514, Invitrogen) was added at a final concentration of 20 nM and incubated for 20 min at 37 °C. Afterward, cells were washed with PBS, and fluorescence was measured using a flow cytometer. Data were analyzed using FlowJo software. The mean fluorescence intensity of mitochondrial mass was calculated for each sample. Statistical analysis All values are presented as the mean ± SD. Statistical significance was defined as p < 0.05, and the results were annotated as follows: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns: not significant. Comparisons involving more than two groups were analyzed using one-way or repeated measures ANOVA, followed by Tukey’s post-hoc test, or two-way ANOVA with Tukey’s correction, as appropriate. Results IGF2 enhances IGF1R/IGF2R activation and promotes proliferation in huSCs IGFs play a crucial role in skeletal muscle development by regulating both the proliferation and differentiation of stem cells. An overview of the experimental design, including isolation, expansion, IGF2 treatment, and the differentiation timeline, is provided in Supplementary Figure S1. In this study, we investigated the effects of IGF2 on huSCs, focusing on the activation of IGF1/2 receptors (IGF1R/2R) and cellular proliferation. First, we assessed how increasing IGF2 concentrations influence IGF1R/2R activation. Western blot analysis revealed that total IGF1R and IGF2R levels remained consistent across all treatments and conditions. In growth medium (GM), IGF2 induced only modest IGF1R phosphorylation and minimal IGF2R phosphorylation. In contrast, differentiating cells maintained in differentiation medium (DM) exhibited strong activation of both receptors, even at low IGF2 concentrations (Fig. 1A). These results suggest that receptor responsiveness to IGF2 is highly dependent on the extracellular environment, with reduced receptor saturation in DM facilitating more robust signaling and supporting efficient differentiation. IGF2 enhances IGF1R/IGF2R activation and promotes proliferation in huSCs. (A) huSCs were seeded in two different culture conditions: myogenic cell growth medium (GM) and myogenic cell differentiation medium (DM). They were then stimulated with low (5 ng/ml) and high (500 ng/ml) concentrations of recombinant human IGF2 for 2 days under GM and 1 week under DM conditions prior to protein collection. The protein levels of IGF1R, IGF2R, phosphorylated IGF1R (P-IGF1R), and phosphorylated IGF2R (P-IGF2R) were measured by western blotting. Quantification of the protein levels of IGF1R, P-IGF1R, IGF2R, and P-IGF2R was performed using ImageJ. Statistical comparisons among groups were performed using two-way ANOVA followed by Tukey’s post hoc test. (B) huSCs were treated with low and high doses of IGF2 for 24 and 48 h. Cells were then incubated for 2 h in EdU labeling solution. EdU+ cells were analyzed by flow cytometry. Data are presented as mean ± SD and analyzed by two-way ANOVA with Tukey’s post hoc test. (C-D) The expression of IGF2 was targeted using lentiviral-based short hairpin RNA (shRNA). The mRNA (C) and protein (D) levels of IGF2 were measured by quantitative PCR and western blotting, respectively. Data are presented as mean ± SD; statistical analysis was performed using one-way ANOVA with Tukey’s post hoc test. (E) IGF2KD huSCs were treated with 300 ng of recombinant human IGF2. Each group of cells was cultured in 6-well plates at a seeding density of 1 × 10⁵ cells/well in growth medium (GM). The cells were then stained with trypan blue to identify dead versus live cells and counted using a hemocytometer at different time points (24, 48, and 72 h). Two-way repeated-measures ANOVA with post hoc test was used for statistical analysis. (F) EdU+ cells were measured by flow cytometry at 24 and 48 h. Two-way ANOVA with Tukey’s post hoc test was used for statistical analysis. All experiments were repeated three times. Data are presented as mean ± SD. ***p < 0.001, ****p < 0.0001; ns: not significant To evaluate the effect of IGF2 on cell proliferation, an EdU incorporation assay was performed 24 and 48 h after treatment with low (L-IGF2) or high (H-IGF2) concentrations of IGF2. As shown in Fig. 1B, IGF2 treatment significantly increased the percentage of proliferating cells compared to the untreated control at all time points. At 24 h, both L-IGF2 and H-IGF2 treatments significantly elevated cell proliferation compared to the control group. At 48 h, the percentage of proliferating cells decreased across all groups; however, IGF2 treatment still resulted in a significant increase relative to the control (Fig. 1B, S2). To further confirm the effects of IGF2 on huSC proliferation, we knocked down endogenous IGF2 using lentiviral-based shRNA. Real-time PCR and western blot analyses confirmed the successful reduction in IGF2 expression (Fig. 1C, D). Cell counting and EdU assays showed that IGF2 knockdown reduced cell growth and proliferation in huSCs (Fig. 1E, F). When IGF2KD huSCs were treated with 300 ng of recombinant human IGF2, cell growth and proliferation were nearly restored (Fig. 1E, F). These data indicate that IGF2 plays a critical role in huSC proliferation. Collectively, these findings demonstrate that IGF2 not only enhances IGF1R/2R signaling, particularly in differentiating myogenic cells, but also critically supports huSC proliferation. IGF2 effects on myogenic gene expression To investigate the effects of IGF2 on myogenic gene expression during both proliferation and differentiation, huSCs were treated with low (L-IGF2) and high (H-IGF2) concentrations of IGF2 in growth medium (GM) or differentiation medium (DM), and the mRNA levels of PAX7, MYOD1, and MYHC were quantified through qRT-PCR. In GM, PAX7, a key marker of satellite cell identity, was significantly upregulated by both L-IGF2 and H-IGF2 compared to the control (Fig. 2A). However, MYOD1 and MYHC expression levels were not significantly different (Fig. 2B, C), which is consistent with the maintenance of the proliferative stem/progenitor state. In DM, which supports terminal differentiation under low-serum conditions [31], PAX7 expression showed a non-significant trend toward an increase following IGF2 treatment (Fig. 2D). Although PAX7 is generally expected to decline as differentiation progresses [26], this trend may reflect the early differentiation time point at which cells were collected. At this stage, a subset of progenitor cells still retains stem cell identity while initiating differentiation. In contrast, MYOD1 and MYHC were significantly and dose-dependently upregulated (Fig. 2E, F), consistent with the activation of the differentiation program. These findings suggest that IGF2 selectively enhances PAX7 expression during the proliferative phase and promotes MYOD1 and MYHC expression during differentiation. This indicates a stage-specific regulatory role for IGF2 in myogenesis. IGF2 effects on myogenic gene expression. (A-F) huSCs were seeded in proliferative (GM: growth medium) and differentiated (DM: differentiation medium) culture conditions. The cells were then stimulated with low (5 ng/ml) and high (500 ng/ml) concentrations of IGF2. PAX7, MYOD1, and MYHC expression were measured by qRT-PCR. All experiments were repeated three times, and group comparisons were analyzed by one-way ANOVA with Tukey’s post-hoc multiple comparison test. Data are presented as mean ± SD. *p < 0.05, **p < 0.01; ns: not significant IGF2 knockdown impairs myogenic differentiation and myotube fusion in huSCs To determine the role of IGF2 in human myogenic differentiation, we analyzed the effects of IGF2 knockdown and exogenous IGF2 supplementation in huSCs using western blotting, immunostaining, and fusion index quantification. IGF2 knockdown (IGF2KD) in huSCs led to a significant reduction in MYOG and MYHC protein levels compared to scramble control cells, indicating impaired myogenic differentiation. Supplementation of IGF2KD cells with recombinant human IGF2 restored MYOG and MYHC expression, though not to the levels observed in control cells (Fig. 3A). Immunofluorescence staining for MYHC revealed abundant multinucleated myotubes in control huSC cultures (Scramble + anti-MYHC). In contrast, IGF2KD cells exhibited a substantial decrease in the number of myotubes, consistent with defective myotube fusion. Addition of IGF2 to IGF2KD cells increased the number of myotubes, demonstrating partial rescue of the myotube fusion phenotype (Fig. 3B, C). Pairwise comparisons between the scramble and IGF2KD + rIGF2 groups further revealed that, although the fusion index was significantly higher in the IGF2KD + rIGF2 group compared to IGF2KD cells, it remained significantly lower than in the scramble control, indicating that IGF2 supplementation only partially restored differentiation capacity. These results demonstrate that IGF2 is essential for efficient myogenic differentiation and myotube formation in huSCs. Loss of IGF2 impairs both differentiation marker expression and myotube fusion, while exogenous IGF2 can partially rescue these defects. IGF2 knockdown impairs myogenic differentiation and myotube fusion in huSCs. (A) The IGF2 gene was silenced using shRNA in huSCs. IGF2KD huSCs were treated with 300 ng/ml of recombinant human IGF-2 (rIGF2). Cells were plated at a density of 1 × 10⁵ cells/well in ECM-coated six-well plates in growth medium (GM). Seventy-two hours later, cells were induced to differentiate into myotubes in DMEM containing 5% horse serum for two weeks. The protein levels of MYOG and MYHC were measured by western blotting. Quantification of MYOG and MYHC protein levels was performed using ImageJ. (B) The cells were immunostained with a MYHC antibody (green) and DAPI (blue). Scale bar = 250 μm. (C) The fusion index was quantified for each experimental group. Labeled nuclei were counted using ImageJ software and expressed as a percentage of the total nuclei. The fusion index was defined as the number of nuclei within myotubes divided by the total number of nuclei. All experiments were repeated three times, and group comparisons were analyzed by one-way ANOVA with Tukey’s post-hoc multiple comparison test. Data are presented as mean ± SD. **p < 0.01, ***p < 0.001, ****p < 0.0001; ns: not significant IGF2-induced expression of myogenic markers is predominantly mediated by IGF1R signaling To determine whether IGF2 increases myogenic differentiation through IGF1R or IGF2R, we respectively blockaded IGF1R and IGF2R in huSCs in vitro. The most effective doses in this experiment for functional blockade (loss of phosphorylation) with acceptable receptor levels and no loading artifacts were 0.6 µM IGF1R inhibitor and 8 µg/ml anti-IGF2R antibody (Fig. 4A, B). Western blot analysis was performed to investigate the effects of IGF2 on the expression of myogenic markers and to evaluate the specific contributions of IGF1R and IGF2R pathways. The expression levels of MYOG and MYHC, key proteins involved in muscle differentiation and maturation, were assessed under two experimental conditions: IGF1R inhibition (0.6 µM inhibitor) and IGF2R neutralization (8 µg/ml antibody). For each condition, cells were treated with no IGF2 (Ctrl), low concentration of IGF2 (L-IGF2), or high concentration of IGF2 (H-IGF2). Under normal conditions, IGF2 treatment significantly increased the expression of both MYOG and MYHC. Compared to the control, both L-IGF2 and H-IGF2 markedly upregulated MYOG and MYHC levels, with a more pronounced effect observed for MYOG (Fig. 4C). These findings indicate that IGF2 positively regulates the expression of muscle differentiation markers. IGF2-induced expression of myogenic markers is predominantly mediated by IGF1R signaling. (A-B) huSCs were treated with different doses of IGF1R inhibitor (NVP-AEW541) and IGF2R neutralizing antibody (anti-IGF2R) to inhibit the signaling pathways. Total and phosphorylated IGF1R and IGF2R were measured by western blotting to assess the efficiency of the blockade. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post-hoc comparison for multiple groups. (C-E) After identifying the optimal dose of IGF1R inhibitor and anti-IGF2R, huSCs were treated with high (500 ng/ml) and low (5 ng/ml) concentrations of IGF2. The differentiation markers, such as MYOG and MYHC, were analyzed after 5 days in differentiation medium using western blotting (C) and immunofluorescence (D). Scale bar = 100 μm. The fusion index for each experimental group was measured (E). All experiments were repeated three times, and group comparisons were analyzed by two-way ANOVA with Tukey’s post-hoc multiple comparison test. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns: not significant When IGF1R signaling was inhibited, the stimulatory effect of IGF2 on myogenic protein expression was significantly attenuated. The upregulation of MYOG by L-IGF2 and H-IGF2 was significantly reduced compared to the normal condition. Similarly, MYHC expression showed minimal response to IGF2 treatment in the presence of the IGF1R inhibitor (Fig. 4C). This suggests that IGF1R signaling plays a critical role in mediating IGF2’s effects on muscle differentiation. In contrast, neutralization of IGF2R did not substantially impair IGF2’s ability to enhance myogenic protein expression. Both MYOG and MYHC showed increased expression with IGF2 treatment despite IGF2R blockade, exhibiting patterns similar to those observed under control conditions (Fig. 4C). However, MYHC levels were reduced in both IGF1R- and IGF2R-inhibited groups compared to the control. Collectively, these findings suggest that IGF2R may not be essential for IGF2-mediated regulation of muscle differentiation markers. Quantification of the fusion index showed that high-dose IGF2 significantly increased myotube formation under normal conditions, while low-dose IGF2 did not induce a significant change. Inhibition of IGF1R resulted in a marked reduction in the fusion index. Although low-dose IGF2 produced only a slight, non-significant increase, higher doses led to a clear, dose-dependent enhancement of fusion. These results indicate that IGF2-driven fusion is largely dependent on IGF1R signaling, and that at elevated concentrations, exogenous IGF2 may also interact with other receptors, such as the insulin receptor. In contrast, IGF2R blockade did not impair IGF2-induced fusion; fusion indices remained similar to or higher than those of the controls with IGF2 treatment (Fig. 4D, E). These results confirm that IGF2 promotes the expression of muscle differentiation markers and myoblast fusion predominantly through IGF1R, rather than IGF2R. IGF2 induces metabolic reprogramming by modulating glucose uptake, glycolytic output, and glycolytic gene expression To investigate the effects of IGF2 on cellular glucose metabolism, we measured glucose uptake, glycolytic output, ATP production, and the expression of key glycolytic enzymes under control (Ctrl), low IGF2 and high IGF2 conditions. Glucose uptake, assessed by 2-NBDG fluorescence, was significantly reduced in both L-IGF2 and H-IGF2 groups compared to the control (Fig. 5A). Similarly, lactate production was significantly decreased in the L-IGF2 and H-IGF2 groups compared to the control (Fig. 5B), indicating a suppression of glycolytic flux at higher IGF2 concentrations. In contrast, ATP levels were markedly increased in the IGF2-treated group compared to the control, suggesting a shift toward more efficient energy production (Fig. 5C). Analysis of glycolytic enzyme gene expression revealed that HK2 and PGAM1 mRNA levels were significantly decreased in the H-IGF2 group compared to the control (Fig. 5D, E). Conversely, ENO1, PFK1, and PKM2 expression were significantly upregulated in the H-IGF2 group. The downregulation of HK2, which catalyzes the first committed step of glycolysis, and PGAM1, a late glycolytic enzyme, aligns with the observed reductions in glucose uptake and lactate production, indicating a decrease in overall glycolytic throughput. In contrast, the upregulation of PFK1, ENO1, and PKM2 likely represents a compensatory adaptation to maintain controlled flux through the key regulatory and terminal steps of glycolysis, thus optimizing pyruvate supply for mitochondrial oxidative phosphorylation (Fig. 5F-H). Collectively, these results demonstrate that IGF2 modulates glucose metabolism by reducing glucose uptake and glycolytic output while enhancing ATP production and differentially regulating glycolytic gene expression, indicative of metabolic reprogramming in response to IGF2. IGF2 induces metabolic reprogramming by modulating glucose uptake, glycolytic output, and glycolytic gene expression. (A-C) huSCs were seeded in differentiated culture conditions and then stimulated with low (5 ng/ml) and high (500 ng/ml) concentrations of IGF2. Cell culture supernatants were collected to measure glucose uptake (A), lactate levels (B), and ATP production (C). (D-H) qRT-PCR analysis of key enzymes in glycolytic metabolism was performed in control and IGF2-treated groups. All experiments were repeated three times, and group comparisons were analyzed by one-way ANOVA with Tukey’s post-hoc multiple comparison test. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns: not significant IGF2 enhances mitochondrial respiration and biogenesis To investigate the effect of IGF2 on mitochondrial structure, function, and biogenesis during muscle differentiation, huSCs were treated with low and high doses of IGF2 under differentiation conditions for 3 days. As shown in Fig. 6A, both L-IGF2 and H-IGF2 groups exhibited a higher oxygen consumption rate (OCR) compared to the control group during the mitochondrial stress test, particularly following FCCP injection, indicating increased mitochondrial respiratory activity (Fig. 6A). In this assay, basal respiration was measured before the addition of oligomycin (pre-oligo). ATP-linked respiration was determined from the decrease in OCR after oligomycin treatment. Proton leak was calculated from the remaining OCR following oligomycin injection, and maximal respiration was measured after FCCP stimulation. The final injection of rotenone and antimycin A defined non-mitochondrial respiration. Quantitative analysis revealed that both basal and maximal respiration were significantly elevated in both L-IGF2 and H-IGF2 groups relative to the control (Fig. 6B, C). Non-mitochondrial respiration and proton leak did not show significant differences among groups (Fig. 6D, E). Further analysis revealed that ATP production and spare respiratory capacity were markedly increased, particularly in the H-IGF2 group (Fig. 6F, G). Mitochondrial content, as assessed by MitoTracker Green fluorescence, was significantly higher in both L-IGF2 and H-IGF2 groups compared to the control (Fig. 6H, S3). Consistent with these findings, western blot analysis demonstrated increased expression of representative subunits from all five mitochondrial respiratory complexes (CI–CV) in IGF2-treated cells (Fig. 6I). Collectively, these results indicate that IGF2 promotes mitochondrial biogenesis and enhances oxidative phosphorylation, leading to increased mitochondrial respiration and ATP production in a dose-dependent manner. IGF2 enhances mitochondrial respiration and biogenesis. (A-G) huSCs were treated with low and high doses of IGF2 under differentiation conditions for 3 days. Oxygen consumption rate (OCR) profiles were determined after the injection of 2.5 mM glucose, followed by 2 mM oligomycin, 1 mM FCCP, and 1 mM each of rotenone and antimycin A, enabling the generation of a mitochondrial stress profile in control and IGF2-treated myotubes. (H) Quantification of MitoTracker Green mean fluorescence intensity (MFI) in control and IGF2-treated cells, indicating increased mitochondrial mass. (I) Western blot analysis of oxidative phosphorylation complex subunits (Complex I: NDUFB8, Complex II: SDHB, Complex III: UQCRC2, Complex IV: MTCO1, Complex V: ATP5A) in control and IGF2-treated cells. β-Actin was used as a loading control. All experiments were repeated three times, and group comparisons were analyzed by one-way ANOVA with Tukey’s post-hoc multiple comparison test. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns: not significant Discussion Our study demonstrates that IGF2 is a key regulator of huSC proliferation, differentiation, and bioenergetics. We show that IGF2 promotes huSC proliferation and differentiation through modulation of MRF expression and activation of the IGF1R signaling pathway. Furthermore, IGF2 treatment significantly enhances mitochondrial respiration and bioenergetic capacity, as evidenced by increased OCR and ATP production. Together, these results reveal that IGF2 is a key modulator, synchronizing growth signaling with metabolic reprogramming during human myogenesis—an area that has remained largely uncharacterized until now. Our findings highlight IGF2’s dual role in regulating both cell fate and energy metabolism in primary human muscle progenitors (Fig. 7). Previous studies have described IGF2’s roles in embryonic development or model cell lines, but its integrated function in adult human stem cells had not been fully defined. Our results bridge this gap, showing that IGF2-driven IGF1R activation promotes both myogenic differentiation and mitochondrial biogenesis, thereby linking the signaling and energetic dimensions of regeneration. A schematic model of the multifaceted effects of IGF2 on huSC biology. IGF2 plays a critical role in regulating huSC biology, primarily through the activation of IGF1R. Binding of IGF2 to IGF1R promotes huSC proliferation and stimulates the expression of myogenic genes, ultimately leading to myotube formation. This process is accompanied by substantial metabolic reprogramming, which includes enhanced mitochondrial biogenesis and respiration, increased oxidative phosphorylation, and elevated ATP production. Simultaneously, IGF2 signaling inhibits glucose uptake and lactate production, further optimizing the bioenergetic capacity of the cells. These coordinated signaling and metabolic effects underscore IGF2’s fundamental role in driving huSC expansion, differentiation, and mitochondrial function Our data further demonstrate that IGF2 significantly enhances huSC proliferation, as shown by increased EdU incorporation and cell counting. IGF2 treatment also increased phosphorylation of IGF1R, suggesting that this receptor may mediate IGF2’s proliferative effects. Although we did not directly test the role of IGF1R inhibition in proliferation, the observed activation of IGF1R, coupled with prior evidence that the IGF2–MAPK/ERK pathway regulates satellite cell proliferation, supports the hypothesis that IGF2 acts through IGF1R to promote huSC proliferation [15]. The MAPK/ERK pathway in proliferating myoblasts operates largely through Shc (Src homology collagen) protein recruitment to IGF1R, which preferentially couples IGF1R to Ras-dependent ERK activation rather than the PI3K/AKT pathway [11]. Knockdown of endogenous IGF2 impaired huSC proliferation, a deficit that was rescued by exogenous IGF2, underscoring IGF2’s essential role. Since huSCs both produce and respond to IGF2, our results suggest that it may function in an autocrine manner [9, 26]. In skeletal muscle, IGF2 originates from multiple sources, including satellite cells, differentiating myofibers, and, to a lesser extent, systemic circulation. Locally produced IGF2 plays the predominant role during regeneration, acting in a spatially restricted paracrine or autocrine manner to stimulate IGF1R signaling within the niche. In contrast, liver-derived circulating IGF2 likely contributes minimally to adult muscle repair. This localized IGF2 production ensures that regenerative signaling is tightly coupled to the activation state and metabolic needs of the satellite cell population [32, 33]. In addition to its proliferative effects, loss of IGF2 markedly reduced huSC differentiation, as shown by decreased MYOG and MYHC expression and reduced myotube formation. Adding recombinant IGF2 partially rescued this phenotype, likely because exogenous IGF2 cannot fully replicate the sustained, localized autocrine IGF2–IGF1R signaling required for optimal differentiation, and is more prone to dilution or IGF2R-mediated clearance. Mechanistically, we determined that the myogenic-promoting effects of IGF2 are predominantly mediated through IGF1R, as its blockade severely impaired differentiation. In contrast, neutralization of IGF2R had a minimal effect, consistent with its primary role in ligand degradation rather than signal activation. This clarifies the signaling paradigm in huSCs, establishing IGF1R as the primary receptor mediating IGF2-dependent differentiation [34]. The functional outcomes of IGF1R activation are critically dependent on the signaling context, driven by distinct patterns of downstream signaling. In proliferating myoblasts under growth conditions, Shc-mediated MAPK/ERK1/2 signaling dominates, promoting proliferation and suppressing differentiation. In contrast, during differentiation, IGF2-IGF1R signaling preferentially activates the PI3K/AKT/mTOR pathway. This shift is facilitated by a relative downregulation of MAPK/ERK activity, creating a signaling environment that facilitates the transition from proliferation to differentiation. This PI3K/AKT/mTOR activation directly influences the myogenic regulatory factor (MRF) network, which coordinates myogenic progression. Specifically, AKT signaling enhances MYOD stability and transcriptional activity by relieving PHB2-mediated inhibition and preventing its proteasomal degradation. This promotes the expression of myogenin and subsequent myotube formation. Furthermore, a positive feedback loop is established, as MYOD and myogenin can upregulate IGF2 expression. This reciprocal regulation between IGF2 signaling and MRFs creates a finely tuned network that integrates growth factor signaling with transcriptional control to govern muscle regeneration [11, 23]. These findings are consistent with previous studies. Aboalola and Han [26] demonstrated that IGF2 promotes the myogenic differentiation of human mesenchymal stem cells by upregulating key markers such as MYOD, MYOG, and MYHC, further confirming IGF2’s direct role in myogenesis through IGF1R activation. Importantly, their study also reported a progressive decrease in PAX7 protein expression, concurrent with an increase in MYOD, MYOG, and MYHC protein levels during differentiation following IGF2 treatment, highlighting the shift from progenitor status toward committed myogenic differentiation. Additionally, Bella et al. [35] found that blockade of IGF2R enhanced muscle regeneration and differentiation, suggesting that IGF2R primarily acts as a modulator of IGF2 availability rather than as a direct effector of its signaling. Together, these studies reinforce the concept that IGF2-driven muscle differentiation is critically dependent on IGF1R signaling through the PI3K/AKT/mTOR pathway, while IGF2R serves a more regulatory function in modulating extracellular IGF2 levels. A particularly novel aspect of this study is the detailed analysis of IGF2-induced metabolic reprogramming, which is essential for myogenic maturation. Our findings show that IGF2 treatment significantly reduced glycolytic activity, as evidenced by decreased glucose uptake and lactate production, alongside downregulation of key glycolytic enzymes, including HK2 and PGAM1. This metabolic shift away from glycolysis parallels the well-established transition during myogenic differentiation, wherein proliferating satellite cells—initially dependent on glycolysis—undergo metabolic reprogramming to meet the bioenergetic demands of differentiated myotubes [36]. Despite this reduction in glycolysis, ATP levels increased, reflecting enhanced mitochondrial energy production, a hallmark of metabolic reprogramming during myogenic differentiation. This apparent discrepancy likely reflects a shift to alternative fuels, such as fatty acids or glutamine, which are present in the differentiation medium and can support mitochondrial respiration independently of glucose. Fatty acid β-oxidation and glutaminolysis generate NADH and FADH₂, feeding the electron transport chain and sustaining oxygen consumption, consistent with known metabolic adaptations during differentiation [37]. IGF2 enhanced mitochondrial respiration, as evidenced by elevated basal oxygen consumption rate, maximal respiration, ATP production, and spare respiratory capacity. These metabolic changes were accompanied by increased mitochondrial mass and upregulation of key oxidative phosphorylation complex subunits, indicating stimulated mitochondrial biogenesis and function [38–40]. The metabolic reprogramming observed in our study is consistent with recent findings that show IGF2 promotes mitochondrial biogenesis through the PGC1α/NRF1/TFAM signaling axis [41]. This pathway is central in coordinating nuclear and mitochondrial gene expression during myogenic differentiation [42, 43]. Additionally, IGF2 regulates BNIP3-mediated mitophagy to maintain mitochondrial quality during myoblast differentiation, ensuring the removal of dysfunctional mitochondria while generating new, functional mitochondria [39, 41, 44]. IGF2 deficiency impairs mitochondrial respiration, reduces membrane potential, and increases oxidative stress, underscoring its crucial role in maintaining mitochondrial integrity through the IGF2-SIRT1-PGC1α pathway [39, 45]. This signaling cascade constitutes a fundamental mechanism by which IGF2 orchestrates the metabolic transition required for successful myogenic differentiation. The metabolic reprogramming induced by IGF2 is not merely a consequence of differentiation but rather an active driver of myogenic progression [46]. During normal muscle development, satellite cells undergo a metabolic shift from glycolysis toward increased reliance on mitochondrial oxidative phosphorylation, which is essential for meeting the energy demands of mature muscle fibers. This transition is particularly important because glycolysis and glycolytic capacity are reduced during differentiation, supporting the notion that myogenic maturation requires enhanced oxidative metabolism [36, 47]. The metabolic changes we observed are consistent with the broader understanding that metabolic reprogramming is a novel regulator of skeletal muscle development and regeneration. Enhanced mitochondrial function provides sustained energy production necessary for muscle contraction, protein synthesis, and cellular maintenance in differentiated myotubes [48]. The comprehensive nature of this work—linking IGF2’s effects on proliferation, differentiation, and metabolism within the same primary human model—represents a significant advancement over previous fragmented studies. The findings of this study have significant implications for understanding the role of IGF2 in muscle development and regeneration. By promoting both the proliferation and differentiation of huSCs, IGF2 appears to play a dual role in muscle repair and regeneration. Its ability to enhance mitochondrial function and bioenergetic capacity further underscores its importance in maintaining muscle homeostasis and supporting the high energy demands of muscle cells during regeneration [39]. These effects are particularly relevant in the context of muscle injury or diseases, where impaired muscle regeneration and metabolic dysfunction are prevalent features. Moreover, the specific role of IGF2 in huSCs underscores its potential as a therapeutic target for muscle-related disorders. For example, enhancing IGF2 signaling could promote muscle regeneration in conditions such as muscular dystrophy or age-related sarcopenia, where satellite cell function is compromised [35, 49]. Conversely, targeting IGF2 signaling may help mitigate the pathological effects of excessive muscle growth or metabolic dysregulation in certain diseases [50]. IGF2 has been shown to promote muscle regeneration by enhancing mitochondrial function and myoblast differentiation, with therapeutic implications for muscle-related diseases such as muscular dystrophy and age-related sarcopenia. Moreover, blocking the IGF2R in dystrophic mice significantly improves muscle regeneration and recovery of muscle function, suggesting that IGF2 signaling could be manipulated to enhance muscle repair in muscular dystrophy [35, 39, 49]. Finally, the role of IGF2 in enhancing mitochondrial biogenesis and function further supports its potential for therapeutic applications in conditions where muscle regeneration is impaired, such as Duchenne muscular dystrophy or age-related muscle decline. While this study provides valuable insights into the role of IGF2 in huSCs, several limitations should be acknowledged. Most notably, the in vitro nature of the experiments limits the direct applicability of these findings to in vivo conditions, where the muscle regeneration environment is far more complex, involving interactions with other cell types, extracellular matrix components, and systemic factors. Future studies should investigate IGF2 modulation in animal or patient-derived models to validate its regenerative potential in physiological contexts. Further mechanistic work is also needed to dissect how IGF2-driven metabolic remodeling intersects with other pathways, such as Notch and Wnt signaling, in coordinating satellite cell fate. In conclusion, this study establishes IGF2 as a central regulator that bridges growth factor signaling and mitochondrial metabolism in primary huSCs. By elucidating this integrated regulatory network, we provide new mechanistic insights and identify IGF2 as a potential therapeutic modulator for enhancing muscle regeneration and metabolic health. Supplementary information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Acknowledgements Not applicable. Author contributions Ramouna Voshtani: Writing-original draft, Writing-review & editing, Validation, Methodology, Investigation, Formal analysis. Pengbo Hou: Writing-review & editing, Investigation. Zhanhong Liu: Investigation. Lijuan Cao: Methodology. Chao Feng: Methodology. Changshun Shao: Supervision, Conceptualization. Yufang Shi: Supervision, Funding acquisition, Conceptualization. Jiankai Fang: Writing-review & editing, Supervision, Funding acquisition, Conceptualization. All authors read and approved the final manuscript. Funding This study was supported by grants from the National Natural Science Foundation of China (82570095, 82202032, U24A20379 and 82430086), Basic Research Program of Jiangsu Province (BK20243007), Jiangsu Province International Joint Laboratory for Regenerative Medicine Fund, Suzhou Foreign Academician Workstation Fund (SWY202202) and Project of MOE Key Laboratory of Geriatric Diseases and Immunology (KJS2603). Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Human skeletal muscle tissue was obtained with informed consent and in compliance with the Ethics Committee of the First Affiliated Hospital of Soochow University (Approval Number: ECSU-201900214). The protocol for macaque muscle tissue isolation was also approved by the Ethics Committee of Soochow University (Approval Number: ECSU-201800099). Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Data Availability Statement No datasets were generated or analysed during the current study.